Floatz logo

ABATACEPT RECOMBINANT

Major Depressive Disorder

Emory Universityprotein_peptidePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

129 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB
DESVENLAFAXINE
Pfizer
Phase 4BBB
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL
Massachusetts General Hospital
Phase 4BBB
MIDAZOLAM
Joshua Rosenblat
Phase 4BB

View all 50 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →